Cerebellar ataxias: an update.


Journal

Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 4 12 2019
medline: 20 1 2021
entrez: 3 12 2019
Statut: ppublish

Résumé

Providing an update on the pathophysiology, cause, diagnosis and treatment of cerebellar ataxias. This is a group of sporadic or inherited disorders with heterogeneous clinical presentation and notorious impact on activities of daily life in many cases. Patients may exhibit a pure cerebellar phenotype or various combinations of cerebellar deficits and extracerebellar deficits affecting the central/peripheral nervous system. Relevant animal models have paved the way for rationale therapies of numerous disorders affecting the cerebellum. Clinically, the cerebellar syndrome is now divided into a cerebellar motor syndrome, vestibulocerebellar syndrome and cerebellar cognitive affective syndrome with a novel clinical scale. This subdivision on three cornerstones is supported by anatomical findings and neuroimaging. It is now established that the basal ganglia and cerebellum, two major subcortical nodes, are linked by disynaptic pathways ensuring bidirectional communication. Inherited ataxias include autosomal recessive cerebellar ataxias (ARCAs), autosomal dominant spinocerebellar ataxias and episodic ataxias and X-linked ataxias. In addition to the Movement Disorders Society genetic classification of ARCAs, the classification of ARCAs by the Society for Research on the Cerebellum and Ataxias represents major progress for this complex subgroup of cerebellar ataxias. The advent of next-generation sequencing has broadened the spectrum of cerebellar ataxias. Cerebellar ataxias require a multidisciplinary approach for diagnosis and management. The demonstration of anatomical relationships between the cerebellum and basal ganglia impacts on the understanding of the cerebello-basal ganglia-thalamo-cortical system. Novel therapies targeting deleterious pathways, such as therapies acting on RNA, are under development.

Identifiants

pubmed: 31789706
doi: 10.1097/WCO.0000000000000774
pii: 00019052-202002000-00023
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

150-160

Références

Kuo SH. Ataxia. Continuum 2019; 25:1036–1054.
Louis ED. Essential tremor and the cerebellum. Handb Clin Neurol 2018; 155:245–258.
Habas C, Manto M. Probing the neuroanatomy of the cerebellum using tractography. Handb Clin Neurol 2018; 154:235–249.
Rexach J, Lee H, Martinez-Agosto JA, et al. Clinical application of next-generation sequencing to the practice of neurology. Lancet Neurol 2019; 18:492–503.
Beaudin M, Matilla-Dueñas A, Soong BW, et al. The classification of autosomal recessive cerebellar ataxias: a consensus statement from the Society for Research on the Cerebellum and Ataxias Task Force. Cerebellum 2019; doi: 10.1007/s12311-019-01052-2. [Epub ahead of print].
doi: 10.1007/s12311-019-01052-2.
Downs AM, Roman KM, Campbell SA, et al. The neurobiological basis for novel experimental therapeutics in dystonia. Neurobiol Dis 2019; 130:104526.
Stoodley CJ, Schmahmann JD. Functional topography of the human cerebellum. Handb Clin Neurol 2018; 154:59–70.
Apps R, Hawkes R, Aoki S, et al. Cerebellar modules and their role as operational cerebellar processing units: a consensus paper. Cerebellum 2018; 17:654–682.
Caligiore D, Pezzulo G, Baldassarre G, et al. Consensus paper: towards a systems-level view of cerebellar function: the interplay between cerebellum, basal ganglia, and cortex. Cerebellum 2017; 16:203–229.
Bologna M, Berardelli A. The cerebellum and dystonia. Handb Clin Neurol 2018; 155:259–272.
White JJ, Sillitoe RV. Genetic silencing of olivocerebellar synapses causes dystonia-like behaviour in mice. Nat Commun 2017; 8:14912.
Feil K, Strobl R, Schindler A, et al. What is behind cerebellar vertigo and dizziness? Cerebellum 2019; 18:320–332.
Adamaszek M, D’agata F, Ferrucci R, et al. Consensus paper: cerebellum and emotion. Cerebellum 2017; 16:552–576.
Catsman-Berrevoets C, Patay Z. Cerebellar mutism syndrome. Handb Clin Neurol 2018; 155:273–288.
Schmahmann JD. Pediatric postoperative cerebellar mutism syndrome, cerebellar cognitive affective syndrome, and posterior fossa syndrome: historical review and proposed resolution to guide future study. Childs Nerv Syst 2019; doi:10.1007/s00381-019-04253-6.
doi: 10.1007/s00381-019-04253-6
Popa LS, Ebner TJ. Cerebellum, predictions and errors. Front Cell Neurosci 2019; 12:524.
Hoche F, Guell X, Vangel MG, et al. The cerebellar cognitive affective/Schmahmann syndrome scale. Brain 2018; 141:248–270.
Heleven E, van Dun K, Van Overwalle F. The posterior Cerebellum is involved in constructing social action sequences: an fMRI study. Sci Rep 2019; 9:11110.
Van Overwalle F, De Coninck S, Heleven E, et al. The role of the cerebellum in reconstructing social action sequences: a pilot study. Soc Cogn Affect Neurosci 2019; 14:549–558.
Hadjivassiliou M, Martindale J, Shanmugarajah P, et al. Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J Neurol Neurosurg Psychiatry 2017; 88:301–309.
Joubert B, Rostásy K, Honnorat J. Immune-mediated ataxias. Handb Clin Neurol 2018; 155:313–332.
Diallo A, Jacobi H, Cook A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol 2018; 17:327–334.
Joers JM, Deelchand DK, Lyu T, et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann Neurol 2018; 83:816–829.
Reetz K, Rodríguez-Labrada R, Dogan I, et al. Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. Ann Clin Transl Neurol 2018; 5:128–137.
de Assis AM, Saute JAM, Longoni A, et al. Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3/Machado-Joseph disease. Front Neurol 2017; 8:485.
Raposo M, Bettencourt C, Ramos A, et al. Promoter variation and expression levels of inflammatory genes IL1A, IL1B, IL6 and TNF in blood of spinocerebellar ataxia type 3 (SCA3) patients. Neuromolecular Med 2017; 19:41–45.
Wilke C, Bender F, Hayer SN, et al. Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol 2018; 265:1618–1624.
Byrne LM, Rodrigues FB, Johnson EB, et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. Sci Transl Med 2018; 10:
Synofzik M, Puccio H, Mochel F, Schöls L. Autosomal recessive cerebellar ataxias: paving the way toward targeted molecular therapies. Neuron 2019; 101:560–583.
Beaudin M, Klein CJ, Rouleau GA, Dupré N. Systematic review of autosomal recessive ataxias and proposal for a classification. Cerebellum Ataxias 2017; 4:3.
Rossi M, Anheim M, Durr A, et al. International Parkinson and Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement Disorders. The genetic nomenclature of recessive cerebellar ataxias. Mov Disord 2018; 33:1056–1076.
Strupp M, Teufel J, Zwergal A, et al. Aminopyridines for the treatment of neurologic disorders. Neurology 2017; 7:65–76.
Kalla R, Strupp M. Aminopyridines and acetyl-dl-leucine: new therapies in cerebellar disorders. Curr Neuropharmacol 2019; 17:7–13.
Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers 2019; 5:24.

Auteurs

Mario Manto (M)

Cerebellar Ataxia Unit, Department of Neurology, CHU-Charleroi, Charleroi.
Department of Neuroscience, University of Mons, Mons, Belgium.

Jordi Gandini (J)

Cerebellar Ataxia Unit, Department of Neurology, CHU-Charleroi, Charleroi.

Katharina Feil (K)

Department of Neurology and German Center for Vertigo and Balance Disorders (DSGZ), Ludwig Maximilians University, Munich, Germany.

Michael Strupp (M)

Department of Neurology and German Center for Vertigo and Balance Disorders (DSGZ), Ludwig Maximilians University, Munich, Germany.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH